Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: A systematic review and meta-analysis

    Access Status
    Open access via publisher
    Authors
    Lai, T.
    Wang, Shaobin
    Xu, Z.
    Zhang, C.
    Zhao, Y.
    Hu, Y.
    Cao, C.
    Ying, S.
    Chen, Z.
    Li, W.
    Wu, B.
    Shen, H.
    Date
    2015
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Lai, T. and Wang, S. and Xu, Z. and Zhang, C. and Zhao, Y. and Hu, Y. and Cao, C. et al. 2015. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: A systematic review and meta-analysis. Scientific Reports. 5.
    Source Title
    Scientific Reports
    DOI
    10.1038/srep08191
    ISSN
    2045-2322
    School
    Department of Chemical Engineering
    URI
    http://hdl.handle.net/20.500.11937/55515
    Collection
    • Curtin Research Publications
    Abstract

    Currently, limited information is available to clinicians regarding the long-term efficacy of omalizumab treatment for allergic asthma. In this report, we aimed to (i) systematically review the evidence regarding the long-term efficacy of omalizumab in patients with persistent uncontrolled allergic asthma, and to (ii) discuss the cost-effectiveness evidence published for omalizumab in this patient population. A comprehensive search for randomized controlled trials (RCTs 52 weeks) was performed, and six studies met our final inclusion criteria (n = 2,749). Omalizumab was associated with significant improvements in quality of life and the Global Evaluation of Treatment Effectiveness. Omalizumab also allowed patients to completely withdraw from inhaled corticosteroid therapy and did not increase the overall incidence of adverse events. However, there was insufficient evidence that omalizumab reduced the incidence of exacerbations, and the cost-effectiveness of omalizumab varied across studies. Our data indicated that omalizumab use for at least 52 weeks in patients with persistent uncontrolled allergic asthma was accompanied by an acceptable safety profile, but it lacked effect on the asthma exacerbations. Use of omalizumab was associated with a higher cost than conventional therapy, but these increases may be cost-effective if the medication is used in patients with severe allergic asthma.

    Related items

    Showing items related by title, author, creator and subject.

    • An investigation of the current management of asthma in adolescents and children in Saudi Arabia, barriers to optimal care, and the influence of patient education
      Al Thagfan, Sultan Saad (2012)
      The incidence of childhood asthma in the kingdom of Saudi Arabia (KSA) ranges from 4% in some regions to 23% in others. Although international and national guidelines have been issued to improve the management of asthma, ...
    • Burden of disease and benefits of exercise in fixed airway obstruction asthma
      Turner, Sian Elizabeth (2009)
      Background and research questions. The characterization of chronic persistent asthma in an older adult population is not well defined. This is due to the difficulties in separating the diagnosis of asthma from that of ...
    • Vitamin D over the first decade and susceptibility to childhood allergy and asthma
      Hollams, E.; Teo, S.; Kusel, M.; Holt, B.; Holt, K.; Inouye, M.; De Klerk, N.; Zhang, Guicheng; Sly, P.; Hart, P.; Holt, P. (2017)
      Background: Vitamin D (25(OH)D) deficiency has been implicated as a possible risk factor for asthma development, but studies at selected time points measuring 25(OH)D levels during childhood have yielded conflicting ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.